The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An Operative Staging System and a Megavoltage Radiotherapeutic Technic for Cerebellar Medulloblastomas
Abstract
CEREBELLAR MEDULLOBLASTOMA is one of the most common types of primary intracranial tumors in children. The treatment of this tumor, unfortunately, is considered as “one of the darkest chapters in pediatric neurosurgery” (1). Cushing (2) reported an average survival of five and six-tenths months in 14 patients with medulloblastoma who received no postoperative radiotherapy. Ingraham and Matson (3) stated that “to our knowledge, no patient with cerebellar medulloblastoma has ever been cured.” Although medulloblastoma has long been known as the most sensitive primary brain tumor to ionizing radiation, the radiotherapy results for this tumor with respect to long-term survival is still very disappointing. In order to better evaluate the response of medulloblastoma to irradiation and to improve the survival rate, the operative records of 100 consecutive cases of tissue-proved medulloblastoma at the Neurological Institute, Columbia-Presbyterian Medical Center were arbitrarily taken in a period from 1940 to 1967 and were reviewed as to their primary location, extent of invasion, and gross subarachnoid seeding in correlation with radiation dose, technic, and survival results when possible. The age and sex distribution in this series is shown in TABLE I. Since clinical staging is inaccurate and sometimes misleading in many inaccessible human cancers, we have sought to develop an operative staging system for medulloblastomas with the International TNM-staging designation. The letter T stands for the primary tumor, subdivided to T1, T2, T3, T4, according to its size and the extent of involvement. Since there are no lymphatic channels in the brain, the letter N is omitted in our staging. The letter M stands for metastasis. In the cases of medulloblastoma, the cerebrospinal fluid pathway is the most important route of metastasis. The extent of metastasis is subdivided to Mo, Ml, M2, M3. Our proposed operative staging system for cerebellar medulloblastoma is as follows (Fig. 1): T1—Tumor less than 3 em in diameter and limited to the classic midline position in the vermis, the roof of the fourth ventricle, and less frequently to the cerebellar hemispheres. T2—Tumor more than 3 em in diameter, further invading one adjacent structure or partially filling the fourth ventricle. T3—It may be subdivided into T3a and T3b. T3a: Tumor further invading two adjacent structures or completely filling the fourth ventricle with extension into the aqueduct of Sylvius, foramen of Magendie, or foramen of Luschka, thus producing marked internal hydrocephalus. T3b: Tumor arising from the floor of the fourth ventricle or brain stem and filling the fourth ventricle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ingraham, F. D., Bailey, O. T., & Barker, W. F. (1948) · New England Journal of Medicine · doi:10.1056/nejm194802052380601 · Cited by 47
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L. E., Merchant, T. E., Woo, S., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Zeltzer, P. M., Boyett, J. M., Finlay, J. L., Albright, A. L., Rorke, L. B., Milstein, J. M., Allen, J. C., Stevens, K. R., Stanley, P., Li, H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.832 · Cited by 754
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Rutkowski, S., Bode, U., Deinlein, F., Ottensmeier, H., Warmuth-Metz, M., Soerensen, N., Graf, N., Emser, A., Pietsch, T., Wolff, J. E. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042176 · Cited by 751
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Packer, R. J., Sutton, L. N., Elterman, R., Lange, B., Goldwein, J., Nicholson, H. S., Mulne, L., Boyett, J., D'Angio, G., Wechsler-Jentzsch, K., et al. (1994) · Journal of Neurosurgery · doi:10.3171/jns.1994.81.5.0690 · Cited by 504
Taylor, R. E., Bailey, C. C., Robinson, K., Weston, C. L., Ellison, D., Ironside, J., Lucraft, H., Gilbertson, R., Tait, D. M., Walker, D. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.116 · Cited by 353
Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis
Rutkowski, S., von Hoff, K., Emser, A., Zwiener, I., Pietsch, T., Figarella-Branger, D., Giangaspero, F., Ellison, D. W., Garre, M.-L., Biassoni, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2299 · Cited by 323
Histopathologic grading of medulloblastomas: A Pediatric Oncology Group Study
Eberhart, C. G., Kepner, J. L., Goldthwaite, P. T., Kun, L. E., Duffner, P. K., Friedman, H. S., Strother, D. R., & Burger, P. C. (2002) · Cancer · doi:10.1002/cncr.10189 · Cited by 316
Albright, A. L., Wisoff, J. H., Zeltzer, P. M., Boyett, J. M., Rorke, L. B., & Stanley, P. (1996) · Neurosurgery · doi:10.1097/00006123-199602000-00007 · Cited by 308
Thomas, P. R. M., Deutsch, M., Kepner, J. L., Boyett, J. M., Krischer, J., Aronin, P., Albright, L., Allen, J. C., Packer, R. J., Linggood, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3004 · Cited by 305
Grill, J., Renaux, V. K., Bulteau, C., Viguier, D., Levy-Piebois, C., Sainte-Rose, C., Dellatolas, G., Raquin, M.-A., Jambaqué, I., & Kalifa, C. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00177-7 · Cited by 287
Radiation treatment for medulloblastoma: A 21-year review
Berry, M. P., Jenkin, R. D. T., Keen, C. W., Nair, B. D., & Simpson, W. J. (1981) · Journal of Neurosurgery · doi:10.3171/jns.1981.55.1.0043 · Cited by 253
Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.002 · Cited by 210
“Metastatic stage was determined according to Chang’s criteria and pathology was centrally reviewed by a panel of neuropathologists from UK Children’s Cancer and Leukemia Group (CCLG) according to current WHO criteria (Chang et al., 1969; Louis et al., 2007).”
Williamson, D., Schwalbe, E. C., Hicks, D., Aldinger, K. A., Lindsey, J. C., Crosier, S., Richardson, S., Goddard, J., Hill, R. M., Castle, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111162 · Cited by 87
Metadata
- Authors
- Chang, C. H., Housepian, E. M., & Herbert, C.
- Venue
- Radiology
- Published
- 1969-12
- Volume
- 93
- Issue
- 6
- Pages
- 1351-1359
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2133893515
- Cited by
- 778
- References
- 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.